Definitive Healthcare (NASDAQ:DH) Issues Q3 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its third quarter 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.040-0.050 for the period, compared to the consensus EPS estimate of 0.040. The company issued revenue guidance of $54.0 million-$55.0 million, compared to the consensus revenue estimate of $55.5 million. Definitive Healthcare also updated its FY 2026 guidance to 0.180-0.200 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DH shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Bank of America reiterated an “underperform” rating and set a $0.70 price target on shares of Definitive Healthcare in a research report on Monday, June 29th. Robert W. Baird set a $1.10 target price on shares of Definitive Healthcare in a research note on Friday, May 8th. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th. Finally, Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $1.88.

Definitive Healthcare Stock Down 1.9%

Shares of DH opened at $0.70 on Tuesday. The stock has a 50 day moving average price of $0.77 and a 200 day moving average price of $1.11. Definitive Healthcare has a one year low of $0.62 and a one year high of $4.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. The stock has a market capitalization of $73.86 million, a price-to-earnings ratio of -0.43, a PEG ratio of 11.51 and a beta of 1.35.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Monday, August 10th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. The company had revenue of $55.20 million for the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Equities research analysts forecast that Definitive Healthcare will post 0.04 earnings per share for the current fiscal year.

Definitive Healthcare News Summary

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Definitive Healthcare reported second-quarter 2026 adjusted earnings of $0.05 per share, exceeding the $0.04 analyst consensus. Full-year 2026 EPS guidance of $0.18–$0.20 also came in above the $0.16 consensus, suggesting better-than-expected earnings profitability. Definitive Healthcare Q2 Earnings Surpass Estimates
• Positive Sentiment: Management’s full-year EPS outlook was raised or set above current expectations, while third-quarter EPS guidance of $0.04–$0.05 brackets consensus at $0.04. Definitive Healthcare Reports Second-Quarter Results
• Neutral Sentiment: Second-quarter revenue totaled $55.2 million, broadly close to—but slightly below—the $55.47 million consensus estimate. Earnings declined from $0.07 per share a year earlier, indicating that the quarterly beat was modest. Definitive Healthcare Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue guidance is below Wall Street expectations: third-quarter revenue is projected at $54.0 million–$55.0 million versus a $55.5 million consensus, while full-year revenue guidance of $220 million–$222 million trails the $223.6 million consensus. This suggests slower near-term growth and is likely the main source of investor pressure. Definitive Healthcare Reports Second-Quarter Results
• Negative Sentiment: The company continues to report a deeply negative net margin of approximately 76%, reinforcing concerns about overall profitability despite positive EPS and return on equity.

Hedge Funds Weigh In On Definitive Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in Definitive Healthcare by 32.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after buying an additional 4,407 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Definitive Healthcare by 5.8% in the fourth quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after purchasing an additional 6,400 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare in the second quarter valued at about $32,000. Creative Planning increased its position in Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after purchasing an additional 8,428 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Definitive Healthcare during the fourth quarter worth about $35,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.